Merck Healthcare

Merck Healthcare is the healthcare division of the German Merck KGaA group, headquartered in Darmstadt, Germany. Merck KGaA was founded in 1668, making it one of the oldest pharmaceutical and chemical companies in the world. The Healthcare division operates as a distinct unit within the group, alongside the Life Science and Electronics divisions.

Merck Healthcare is engaged in the research, development, manufacturing, and commercialization of prescription drugs and biologic therapies. Its primary focus areas include oncology, neurology, immunology, and fertility. Key named products include Erbitux (cetuximab), a monoclonal antibody for colorectal and head-and-neck cancers; Rebif (interferon beta-1a), a treatment for relapsing multiple sclerosis; and Bavencio (avelumab), a PD-L1 checkpoint inhibitor for certain cancers co-developed and co-commercialized with Pfizer. The fertility portfolio includes Gonal-f (follitropin alfa).

In the multiple sclerosis space, Rebif competes with Biogen's Avonex and Teva's Copaxone. In oncology, Bavencio sits in the checkpoint inhibitor market alongside Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo. A critical point of context: Merck KGaA (Germany) and Merck & Co. (USA) are entirely separate companies that share a common historical origin but have operated independently for over a century.